<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.20331.020</object-id><label>Table 2.</label><caption><p>Top 10 gene sets for lists of genes up- and down-regulated in tumors with <italic>Cdx2<sup>&#8722;/&#8722;</sup></italic> and <italic>Braf<sup>V600E</sup></italic> mutations.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20331.020">http://dx.doi.org/10.7554/eLife.20331.020</ext-link></p><p><supplementary-material id="SD8-data"><object-id pub-id-type="doi">10.7554/eLife.20331.021</object-id><label>Table 2&#8212;source data 1.</label><caption><title>Results of enrichment testing the Molecular Signatures Database (MSigDB) v5.1 for the hallmark collection of 50 gene sets.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20331.021">http://dx.doi.org/10.7554/eLife.20331.021</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20331-table2-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"><p>Up or down genes</p></th><th valign="bottom"><p>Gene set title</p></th><th valign="bottom"><p>Number of genes on list</p></th><th valign="bottom"><p>Number of those genes we selected</p></th><th valign="bottom"><p>P-value (Fisher Exact)</p></th><th valign="bottom"><p>Observed/expected</p></th><th valign="bottom"><p>Rank of gene set</p></th><th valign="bottom"><p>Estimated FDR (Q-value)</p></th></tr></thead><tbody><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</p></td><td valign="bottom"><p>186</p></td><td valign="bottom"><p>69</p></td><td valign="bottom"><p>1.0E-28</p></td><td valign="bottom"><p>4.57</p></td><td valign="bottom"><p>1</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_KRAS_SIGNALING_UP</p></td><td valign="bottom"><p>192</p></td><td valign="bottom"><p>41</p></td><td valign="bottom"><p>7.3E-09</p></td><td valign="bottom"><p>2.63</p></td><td valign="bottom"><p>2</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_HYPOXIA</p></td><td valign="bottom"><p>189</p></td><td valign="bottom"><p>36</p></td><td valign="bottom"><p>1.1E-06</p></td><td valign="bottom"><p>2.35</p></td><td valign="bottom"><p>3</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_COAGULATION</p></td><td valign="bottom"><p>126</p></td><td valign="bottom"><p>27</p></td><td valign="bottom"><p>2.4E-06</p></td><td valign="bottom"><p>2.64</p></td><td valign="bottom"><p>4</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_TNFA_SIGNALING_VIA_NFKB</p></td><td valign="bottom"><p>189</p></td><td valign="bottom"><p>35</p></td><td valign="bottom"><p>3.2E-06</p></td><td valign="bottom"><p>2.28</p></td><td valign="bottom"><p>5</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_UV_RESPONSE_DN</p></td><td valign="bottom"><p>141</p></td><td valign="bottom"><p>28</p></td><td valign="bottom"><p>7.6E-06</p></td><td valign="bottom"><p>2.45</p></td><td valign="bottom"><p>6</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_ANGIOGENESIS</p></td><td valign="bottom"><p>36</p></td><td valign="bottom"><p>12</p></td><td valign="bottom"><p>1.5E-05</p></td><td valign="bottom"><p>4.11</p></td><td valign="bottom"><p>7</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_INFLAMMATORY_RESPONSE</p></td><td valign="bottom"><p>189</p></td><td valign="bottom"><p>32</p></td><td valign="bottom"><p>5.3E-05</p></td><td valign="bottom"><p>2.09</p></td><td valign="bottom"><p>8</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_IL2_STAT5_SIGNALING</p></td><td valign="bottom"><p>193</p></td><td valign="bottom"><p>30</p></td><td valign="bottom"><p>4.2E-04</p></td><td valign="bottom"><p>1.92</p></td><td valign="bottom"><p>9</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Up</p></td><td valign="bottom"><p>HALLMARK_APICAL_JUNCTION</p></td><td valign="bottom"><p>191</p></td><td valign="bottom"><p>29</p></td><td valign="bottom"><p>7.6E-04</p></td><td valign="bottom"><p>1.87</p></td><td valign="bottom"><p>10</p></td><td valign="bottom"><p>0.001</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_CHOLESTEROL_HOMEOSTASIS</p></td><td valign="bottom"><p>72</p></td><td valign="bottom"><p>17</p></td><td valign="bottom"><p>2.7E-09</p></td><td valign="bottom"><p>5.86</p></td><td valign="bottom"><p>1</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_ADIPOGENESIS</p></td><td valign="bottom"><p>191</p></td><td valign="bottom"><p>22</p></td><td valign="bottom"><p>9.3E-06</p></td><td valign="bottom"><p>2.86</p></td><td valign="bottom"><p>2</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_XENOBIOTIC_METABOLISM</p></td><td valign="bottom"><p>194</p></td><td valign="bottom"><p>22</p></td><td valign="bottom"><p>1.2E-05</p></td><td valign="bottom"><p>2.81</p></td><td valign="bottom"><p>3</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_ESTROGEN_RESPONSE_LATE</p></td><td valign="bottom"><p>189</p></td><td valign="bottom"><p>21</p></td><td valign="bottom"><p>2.6E-05</p></td><td valign="bottom"><p>2.76</p></td><td valign="bottom"><p>4</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_MTORC1_SIGNALING</p></td><td valign="bottom"><p>193</p></td><td valign="bottom"><p>21</p></td><td valign="bottom"><p>3.5E-05</p></td><td valign="bottom"><p>2.70</p></td><td valign="bottom"><p>5</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_BILE_ACID_METABOLISM</p></td><td valign="bottom"><p>109</p></td><td valign="bottom"><p>14</p></td><td valign="bottom"><p>1.2E-04</p></td><td valign="bottom"><p>3.19</p></td><td valign="bottom"><p>6</p></td><td valign="bottom"><p>0.000</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_FATTY_ACID_METABOLISM</p></td><td valign="bottom"><p>149</p></td><td valign="bottom"><p>16</p></td><td valign="bottom"><p>3.4E-04</p></td><td valign="bottom"><p>2.67</p></td><td valign="bottom"><p>7</p></td><td valign="bottom"><p>0.004</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_PEROXISOME</p></td><td valign="bottom"><p>101</p></td><td valign="bottom"><p>12</p></td><td valign="bottom"><p>7.4E-04</p></td><td valign="bottom"><p>2.95</p></td><td valign="bottom"><p>8</p></td><td valign="bottom"><p>0.005</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_GLYCOLYSIS</p></td><td valign="bottom"><p>193</p></td><td valign="bottom"><p>18</p></td><td valign="bottom"><p>8.2E-04</p></td><td valign="bottom"><p>2.31</p></td><td valign="bottom"><p>9</p></td><td valign="bottom"><p>0.004</p></td><td/><td/></tr><tr><td valign="bottom"><p>Down</p></td><td valign="bottom"><p>HALLMARK_ESTROGEN_RESPONSE_EARLY</p></td><td valign="bottom"><p>190</p></td><td valign="bottom"><p>17</p></td><td valign="bottom"><p>1.8E-03</p></td><td valign="bottom"><p>2.22</p></td><td valign="bottom"><p>10</p></td><td valign="bottom"><p>0.005</p></td><td/><td/></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>Results of enrichment testing the Molecular Signatures Database (MSigDB) v5.1 for the Hallmark collection of 50 gene sets. We selected genes with significant Cdx2 by Braf interactions, asking that p&lt;0.01 and that the fold-change between Cdx2+Braf and Braf was at least 1.3 times larger (or smaller) than the fold-change between Cdx2 and control, which selected 1453 up distict mouse genes and 767 down mouse genes (out of 22326 distinct mouse genes). We mapped to human genes choosing only 1-to-1 best homologs using NCBI's Homologene version 68, which left 1277 up and 634 down distict human genes, out of a total of 15735 genes. We tested our up and down genes separately for over-representation in 50 Hallmark gene sets using one-sided Fisher Exact tests. Shown are the 10 gene sets in the collection that gave the smallest p-values. The last column gives the estimated false discovery rates (Q-values) based on 100 data sets in which the human gene identifiers were randomly permuted.</p></fn></table-wrap-foot></table-wrap>